🇺🇸 FDA
Patent

US 12109216

Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

granted A61KA61K2300/00A61K31/137

Quick answer

US patent 12109216 (Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome) held by ESSENTIALIS, INC. expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ESSENTIALIS, INC.
Grant date
Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2300/00, A61K31/137, A61K31/155, A61K31/549